Immediate Ban of Benicar Demanded by Consumer Advocacy Group
- Last Updated: August 4th, 2023
Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
Legally Reviewed
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
Fact-Checked
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Immediate Ban of Benicar Demanded by Consumer Advocacy Group
On November 15th, 2017, Public Citizen, a consumer advocacy group with more than 400,000 members filed a Benicar ban petition demanding that the FDA remove popular high blood pressure drugs Azor, Benicar, Benicar HCT and Trebenzor from the market because of their association with a severe gastrointestinal injury, sprue-like enteropathy.
Benicar, Azor, Benicar HCT and Tribenzor are widely prescribed angiotensin II receptor blocker (ARB) high blood pressure drugs containing olmesartan medoxomil.
These four drugs have made Daiichi Sankyo, the manufacturer of all three just under $1 billion dollars annually for the past few years (2014 and 2015).
Yet, the company has been aware of the link to this dangerous GI injury for years.
In the petition filed on November 15th, Public Citizen further noted that these olmesartan containing drugs manufactured by Daiichi Sankyo, Inc. offer no unique clinical benefits as compared to other ARBs so there should be no reason to remain on the market.
Sprue-like enteropathy causes serious morbidity.
Individuals diagnosed with this disease experienced severe weight loss and malnutrition.
Most required hospitalization, with some needing intensive care.
Severe serum electrolyte abnormalities and acute kidney injury were among the complications of the enteropathy experienced by patients.
Studies were able to pin-point the cause of the sprue-like enteropathy as coming from one of these drugs because the symptoms mostly disappeared after discontinuation of the medication and returned when patients started taking the medicine again.
The first olmesartan medoxomil drug was FDA approved in 2002 and within ten years, studies clearly pointed to a link between these drugs and sprue like enteropathy.
Lawsuits filed on behalf of individuals suffering from sprue-like enteropathy allege that Daiichi Sankyo knew about this link and should have warned the public prior to 2012 when case reports were published in scientific medical journals.
The FDA warned of the link between Benicar and enteropathy in 2013 based on the review of 23 individuals reported to the FDA through the FAERS database.
At that time, the FDA required that Daiichi Sankyo change their label to warn the public of the risk of sprue-like enteropathy.
Public Citizen called this label change “weak” and “seriously deficient from a public health perspective.”
In August 2017, Daiiichi Sankyo agreed to pay up to $300 million in a Benicar lawsuit settlement intended compensate approximately 2,300 individuals who suffer from the life-altering disease sprue-like enteropathy.
The FDA will consider the petition and respond to Public Citizen.
Table of Contents
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
